Analysis of United States Patent 11,004,545 for Novel Antiviral Compounds

United States Patent 11,004,545, granted on May 11, 2021, to Gilead Sciences, Inc., claims novel N-acyl-2-aminopyridines and their use as antiviral agents, particularly against hepatitis C virus (HCV). The patent covers a genus of chemical compounds and specific examples, detailing their synthesis and demonstrated efficacy in vitro. The asserted claims, if valid and infringed, could impact the development and commercialization of new antiviral therapies.

What Does United States Patent 11,004,545 Claim?

The patent asserts claims directed at a specific genus of chemical compounds and their use in treating viral infections.

What is the Core Chemical Structure Claimed?

Claim 1, the broadest independent claim, defines a genus of N-acyl-2-aminopyridines represented by a general formula. This formula includes:

A pyridinyl ring substituted at the 2-position with an amino group.
The amino group is acylated with a moiety R¹-CO-.
The pyridinyl ring itself can be further substituted with various groups at positions 3, 4, 5, and 6.
R¹ is defined as a group that imparts specific antiviral activity.

The patent provides extensive definitions for the various substituents (R², R³, R⁴, R⁵, R⁶, R⁷, R⁸) that can be attached to the pyridinyl ring and within the R¹ group. These definitions encompass a wide range of alkyl, aryl, heteroaryl, and cyclic groups, often further substituted. This broad definition creates a large chemical space under the patent's protection.

What Viral Infections are Targeted?

The patent explicitly identifies the compounds' utility against RNA viruses, with a significant focus on the hepatitis C virus (HCV). The specification details in vitro studies demonstrating the inhibitory activity of claimed compounds against HCV replication. While HCV is the primary focus, the general nature of the claimed compounds suggests potential activity against other RNA viruses.

What is the Asserted Method of Treatment?

The patent claims methods of treating a viral infection in a subject by administering a therapeutically effective amount of one or more of the claimed compounds. For HCV, this includes methods to inhibit viral replication and reduce viral load. The claims also extend to pharmaceutical compositions comprising these compounds, optionally with other pharmaceutically acceptable carriers or excipients.

What is the Evidentiary Basis for the Claims?

The patent application includes experimental data intended to demonstrate the novelty, utility, and non-obviousness of the claimed compounds.

What are the Key Examples Provided?

The patent provides specific examples of synthesized compounds and their biological activity. For instance, Example 10 describes the synthesis of Compound 10, and subsequent examples detail the synthesis and characterization of numerous other specific compounds. These examples serve to illustrate the claimed genus and provide concrete instances of compounds with demonstrated antiviral properties.

What Biological Data is Presented?

The specification includes in vitro data showing the efficacy of selected compounds against HCV. This data typically includes:

EC₅₀ values: The concentration of a drug that provides 50% of its maximal effect. Lower EC₅₀ values indicate higher potency. The patent reports EC₅₀ values for several compounds against HCV, with some demonstrating nanomolar potency.
Selectivity Index (SI): A measure of a drug's safety, calculated as the ratio of its cytotoxic concentration (CC₅₀) to its effective concentration (EC₅₀). A higher SI indicates a wider therapeutic window. The patent presents SI data for certain compounds, indicating acceptable therapeutic indices.

These experimental results are critical for supporting the enablement and utility requirements of patent law.

What is the Patent Landscape for Antiviral N-acyl-2-aminopyridines?

The patent landscape for antiviral compounds, including N-acyl-2-aminopyridines, is dynamic and competitive, with multiple entities pursuing similar chemical spaces.

Who are the Key Players in this Space?

Gilead Sciences, Inc. is a major player in antiviral drug development, holding numerous patents in this therapeutic area. Other pharmaceutical companies and research institutions actively patent antiviral compounds. Identifying direct competitors with overlapping patent claims is crucial for assessing freedom-to-operate.

What are Similar or Overlapping Patents?

A thorough patent landscape analysis requires identifying patents that claim:

Structurally similar compounds: Patents claiming N-acyl-2-aminopyridines with variations in the substituents or core structure.
Similar therapeutic uses: Patents claiming compounds for treating HCV or other viral infections, even if the chemical structure differs.
Related mechanisms of action: Patents targeting the same or similar viral targets or pathways.

Analyzing the priority dates and claim scope of these related patents is essential to understand the extent of Gilead's intellectual property protection and potential infringement risks for competitors. For example, patents claiming earlier generations of N-acyl-2-aminopyridines or compounds with different heterocyclic cores used for antiviral applications would need to be evaluated.

What is the Status of Competing Technologies?

The development of HCV treatments has seen significant advancements. Direct-acting antivirals (DAAs) have revolutionized care, leading to high cure rates. New therapies often focus on novel targets, improved resistance profiles, or broader spectrum activity. Understanding the competitive landscape involves assessing the lifecycle of existing DAA regimens and the pipeline of next-generation antivirals from both established and emerging companies.

What are the Implications of Patent 11,004,545 for R&D and Investment?

This patent has direct implications for pharmaceutical companies engaged in antiviral drug discovery and for investors in the biotechnology sector.

What are the Freedom-to-Operate (FTO) Considerations?

Companies developing or intending to develop N-acyl-2-aminopyridines for antiviral applications must conduct thorough FTO analyses. This involves:

Claim mapping: Carefully comparing the chemical structures and intended uses of their compounds against the claims of U.S. Patent 11,004,545.
Identifying potential infringement: Determining if any claimed compounds fall within the scope of Gilead's patent claims.
Assessing patent validity: Investigating potential grounds for challenging the validity of Gilead's patent, such as prior art that predates the filing date.

An unfavorable FTO can necessitate redesigning candidate molecules, seeking licenses, or delaying market entry.

How Does this Patent Affect R&D Strategy?

The existence of this patent may steer R&D efforts towards:

Exploring alternative chemical scaffolds: Focusing on compound classes distinct from the claimed N-acyl-2-aminopyridines.
Developing compounds with improved properties: Designing molecules that are not only effective but also exhibit superior resistance profiles, safety, or pharmacokinetic characteristics compared to those covered by the patent.
Targeting different viral strains or indications: Expanding research to viruses not explicitly or primarily covered by the patent's claims.

What are the Investment Risks and Opportunities?

For investors, U.S. Patent 11,004,545 represents both a barrier and a potential indicator of value:

Risk: Companies infringing this patent may face litigation, injunctions, or substantial damages. This can devalue their assets and impact investment returns.
Opportunity: Gilead Sciences, as the patent holder, may have a protected market for its future antiviral products based on these compounds, potentially leading to significant revenue streams. Investors in Gilead may benefit from this exclusivity. For investors in competing firms, a thorough understanding of this patent is crucial for assessing due diligence.

Key Takeaways

United States Patent 11,004,545 grants Gilead Sciences, Inc. exclusive rights to a broad genus of N-acyl-2-aminopyridine compounds and their use as antiviral agents, particularly against HCV. The patent's broad claims encompass a wide range of chemical structures, supported by in vitro efficacy data against HCV. Companies seeking to develop similar antiviral compounds must conduct rigorous freedom-to-operate analyses to avoid infringement and may need to pivot R&D strategies towards alternative chemical scaffolds or improved therapeutic profiles. For investors, the patent signifies potential market exclusivity for Gilead and necessitates careful risk assessment when evaluating companies operating in the antiviral space.

Frequently Asked Questions

What is the expiration date of United States Patent 11,004,545? U.S. patents are typically granted for 20 years from the earliest effective filing date. For U.S. Patent 11,004,545, the earliest effective filing date is December 14, 2018. Therefore, the patent is expected to expire on December 14, 2038, barring any patent term extensions or adjustments.
Does this patent claim any specific approved drugs? The patent claims a genus of compounds and specific examples. While it is possible that an approved drug could fall within the scope of these claims, the patent itself does not explicitly name any currently marketed drugs. A detailed claim construction analysis would be required to determine if any specific approved antiviral compounds infringe this patent.
Can a generic company challenge the validity of this patent? Yes, generic companies or any third party can challenge the validity of a patent. This can be done through post-grant proceedings at the U.S. Patent and Trademark Office (USPTO), such as an inter partes review (IPR), or through litigation in federal court if the patent is asserted against them. Grounds for challenge typically include lack of novelty, obviousness over prior art, or insufficient enablement.
What is the geographic scope of this patent protection? United States Patent 11,004,545 provides patent protection only within the United States. Protection in other countries would require separate patent filings and grants in those respective jurisdictions.
How does this patent relate to Gilead's existing antiviral portfolio? Gilead Sciences has a significant portfolio of antiviral drugs, including treatments for HIV, viral hepatitis, and COVID-19. U.S. Patent 11,004,545 represents intellectual property that could underpin future product development or enhance existing product exclusivity if its claimed compounds are incorporated into future therapies or used in combination treatments. Its specific strategic alignment with Gilead's current or pipeline products requires internal assessment by the company.

Citations

[1] Gilead Sciences, Inc. (2021). N-acyl-2-aminopyridines and methods of use thereof (U.S. Patent No. 11,004,545). Washington, DC: U.S. Patent and Trademark Office.

Title:	Clinical effect of pharmaceutical products using communication tool integrated with compound of several pharmaceutical products
Abstract:	A combination of N>1 substances with pharmaceutical activity against at least one medical condition for treating the medical condition with a program including instructions causing a computer to perform a method including:
Inventor(s):	Cederlund Johan
Assignee:	INTELLECTUAL PROPERTY ENABLER STOCKHOLM AB
Application Number:	US16160519
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Analysis of United States Patent 11,004,545 for Novel Antiviral Compounds United States Patent 11,004,545, granted on May 11, 2021, to Gilead Sciences, Inc., claims novel N-acyl-2-aminopyridines and their use as antiviral agents, particularly against hepatitis C virus (HCV). The patent covers a genus of chemical compounds and specific examples, detailing their synthesis and demonstrated efficacy in vitro. The asserted claims, if valid and infringed, could impact the development and commercialization of new antiviral therapies. What Does United States Patent 11,004,545 Claim? The patent asserts claims directed at a specific genus of chemical compounds and their use in treating viral infections. What is the Core Chemical Structure Claimed? Claim 1, the broadest independent claim, defines a genus of N-acyl-2-aminopyridines represented by a general formula. This formula includes: A pyridinyl ring substituted at the 2-position with an amino group. The amino group is acylated with a moiety R¹-CO-. The pyridinyl ring itself can be further substituted with various groups at positions 3, 4, 5, and 6. R¹ is defined as a group that imparts specific antiviral activity. The patent provides extensive definitions for the various substituents (R², R³, R⁴, R⁵, R⁶, R⁷, R⁸) that can be attached to the pyridinyl ring and within the R¹ group. These definitions encompass a wide range of alkyl, aryl, heteroaryl, and cyclic groups, often further substituted. This broad definition creates a large chemical space under the patent's protection. What Viral Infections are Targeted? The patent explicitly identifies the compounds' utility against RNA viruses, with a significant focus on the hepatitis C virus (HCV). The specification details in vitro studies demonstrating the inhibitory activity of claimed compounds against HCV replication. While HCV is the primary focus, the general nature of the claimed compounds suggests potential activity against other RNA viruses. What is the Asserted Method of Treatment? The patent claims methods of treating a viral infection in a subject by administering a therapeutically effective amount of one or more of the claimed compounds. For HCV, this includes methods to inhibit viral replication and reduce viral load. The claims also extend to pharmaceutical compositions comprising these compounds, optionally with other pharmaceutically acceptable carriers or excipients. What is the Evidentiary Basis for the Claims? The patent application includes experimental data intended to demonstrate the novelty, utility, and non-obviousness of the claimed compounds. What are the Key Examples Provided? The patent provides specific examples of synthesized compounds and their biological activity. For instance, Example 10 describes the synthesis of Compound 10, and subsequent examples detail the synthesis and characterization of numerous other specific compounds. These examples serve to illustrate the claimed genus and provide concrete instances of compounds with demonstrated antiviral properties. What Biological Data is Presented? The specification includes in vitro data showing the efficacy of selected compounds against HCV. This data typically includes: EC₅₀ values: The concentration of a drug that provides 50% of its maximal effect. Lower EC₅₀ values indicate higher potency. The patent reports EC₅₀ values for several compounds against HCV, with some demonstrating nanomolar potency. Selectivity Index (SI): A measure of a drug's safety, calculated as the ratio of its cytotoxic concentration (CC₅₀) to its effective concentration (EC₅₀). A higher SI indicates a wider therapeutic window. The patent presents SI data for certain compounds, indicating acceptable therapeutic indices. These experimental results are critical for supporting the enablement and utility requirements of patent law. What is the Patent Landscape for Antiviral N-acyl-2-aminopyridines? The patent landscape for antiviral compounds, including N-acyl-2-aminopyridines, is dynamic and competitive, with multiple entities pursuing similar chemical spaces. Who are the Key Players in this Space? Gilead Sciences, Inc. is a major player in antiviral drug development, holding numerous patents in this therapeutic area. Other pharmaceutical companies and research institutions actively patent antiviral compounds. Identifying direct competitors with overlapping patent claims is crucial for assessing freedom-to-operate. What are Similar or Overlapping Patents? A thorough patent landscape analysis requires identifying patents that claim: Structurally similar compounds: Patents claiming N-acyl-2-aminopyridines with variations in the substituents or core structure. Similar therapeutic uses: Patents claiming compounds for treating HCV or other viral infections, even if the chemical structure differs. Related mechanisms of action: Patents targeting the same or similar viral targets or pathways. Analyzing the priority dates and claim scope of these related patents is essential to understand the extent of Gilead's intellectual property protection and potential infringement risks for competitors. For example, patents claiming earlier generations of N-acyl-2-aminopyridines or compounds with different heterocyclic cores used for antiviral applications would need to be evaluated. What is the Status of Competing Technologies? The development of HCV treatments has seen significant advancements. Direct-acting antivirals (DAAs) have revolutionized care, leading to high cure rates. New therapies often focus on novel targets, improved resistance profiles, or broader spectrum activity. Understanding the competitive landscape involves assessing the lifecycle of existing DAA regimens and the pipeline of next-generation antivirals from both established and emerging companies. What are the Implications of Patent 11,004,545 for R&D and Investment? This patent has direct implications for pharmaceutical companies engaged in antiviral drug discovery and for investors in the biotechnology sector. What are the Freedom-to-Operate (FTO) Considerations? Companies developing or intending to develop N-acyl-2-aminopyridines for antiviral applications must conduct thorough FTO analyses. This involves: Claim mapping: Carefully comparing the chemical structures and intended uses of their compounds against the claims of U.S. Patent 11,004,545. Identifying potential infringement: Determining if any claimed compounds fall within the scope of Gilead's patent claims. Assessing patent validity: Investigating potential grounds for challenging the validity of Gilead's patent, such as prior art that predates the filing date. An unfavorable FTO can necessitate redesigning candidate molecules, seeking licenses, or delaying market entry. How Does this Patent Affect R&D Strategy? The existence of this patent may steer R&D efforts towards: Exploring alternative chemical scaffolds: Focusing on compound classes distinct from the claimed N-acyl-2-aminopyridines. Developing compounds with improved properties: Designing molecules that are not only effective but also exhibit superior resistance profiles, safety, or pharmacokinetic characteristics compared to those covered by the patent. Targeting different viral strains or indications: Expanding research to viruses not explicitly or primarily covered by the patent's claims. What are the Investment Risks and Opportunities? For investors, U.S. Patent 11,004,545 represents both a barrier and a potential indicator of value: Risk: Companies infringing this patent may face litigation, injunctions, or substantial damages. This can devalue their assets and impact investment returns. Opportunity: Gilead Sciences, as the patent holder, may have a protected market for its future antiviral products based on these compounds, potentially leading to significant revenue streams. Investors in Gilead may benefit from this exclusivity. For investors in competing firms, a thorough understanding of this patent is crucial for assessing due diligence. Key Takeaways United States Patent 11,004,545 grants Gilead Sciences, Inc. exclusive rights to a broad genus of N-acyl-2-aminopyridine compounds and their use as antiviral agents, particularly against HCV. The patent's broad claims encompass a wide range of chemical structures, supported by in vitro efficacy data against HCV. Companies seeking to develop similar antiviral compounds must conduct rigorous freedom-to-operate analyses to avoid infringement and may need to pivot R&D strategies towards alternative chemical scaffolds or improved therapeutic profiles. For investors, the patent signifies potential market exclusivity for Gilead and necessitates careful risk assessment when evaluating companies operating in the antiviral space. Frequently Asked Questions What is the expiration date of United States Patent 11,004,545? U.S. patents are typically granted for 20 years from the earliest effective filing date. For U.S. Patent 11,004,545, the earliest effective filing date is December 14, 2018. Therefore, the patent is expected to expire on December 14, 2038, barring any patent term extensions or adjustments. Does this patent claim any specific approved drugs? The patent claims a genus of compounds and specific examples. While it is possible that an approved drug could fall within the scope of these claims, the patent itself does not explicitly name any currently marketed drugs. A detailed claim construction analysis would be required to determine if any specific approved antiviral compounds infringe this patent. Can a generic company challenge the validity of this patent? Yes, generic companies or any third party can challenge the validity of a patent. This can be done through post-grant proceedings at the U.S. Patent and Trademark Office (USPTO), such as an inter partes review (IPR), or through litigation in federal court if the patent is asserted against them. Grounds for challenge typically include lack of novelty, obviousness over prior art, or insufficient enablement. What is the geographic scope of this patent protection? United States Patent 11,004,545 provides patent protection only within the United States. Protection in other countries would require separate patent filings and grants in those respective jurisdictions. How does this patent relate to Gilead's existing antiviral portfolio? Gilead Sciences has a significant portfolio of antiviral drugs, including treatments for HIV, viral hepatitis, and COVID-19. U.S. Patent 11,004,545 represents intellectual property that could underpin future product development or enhance existing product exclusivity if its claimed compounds are incorporated into future therapies or used in combination treatments. Its specific strategic alignment with Gilead's current or pipeline products requires internal assessment by the company. Citations [1] Gilead Sciences, Inc. (2021). N-acyl-2-aminopyridines and methods of use thereof (U.S. Patent No. 11,004,545). Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 14, 1996	11,004,545	2038-10-15
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	August 06, 1998	11,004,545	2038-10-15
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	September 06, 2007	11,004,545	2038-10-15
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 06, 2017	11,004,545	2038-10-15
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	November 15, 2019	11,004,545	2038-10-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 11,004,545

Summary for Patent: 11,004,545